14 insiders reported 20 Form 4 transactions for Trevi Therapeutics, Inc. (TRVI) over the past 18 months (most recent 2026-02-13). Recent activity: NEA 16 GP, LLC (Insider) Buy 1.9M shares, NEA Partners 16, L.P. (Insider) Buy 1.9M shares, New Enterprise Associates 16, L.P. (Insider) Buy 1.9M shares, Makhzoumi Mohamad (Insider) Buy 1.9M shares, Chang Carmen (Insider) Buy 1.9M shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-13 | NEA 16 GP, LLC | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | NEA Partners 16, L.P. | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | New Enterprise Associates 16, L.P. | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | Makhzoumi Mohamad | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | Chang Carmen | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | Behbahani Ali | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | Florence Anthony A. Jr. | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | Walker Paul Edward | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | BASKETT FOREST | Insider | Buy | 1.9M | $2.5M |
| 2026-02-13 | SANDELL SCOTT D | Insider | Buy | 1.9M | $2.5M |
| 2025-12-03 | Galletta Christopher | See Remarks | Buy | 4,225 | $2,155 |
| 2025-03-26 | SCIASCIA THOMAS | Chief Scientific Officer | Buy | 2,631 | $3,762 |
| 2025-03-26 | SCIASCIA THOMAS | Chief Scientific Officer | Sell | 2,631 | $17,365 |
| 2025-03-25 | GOOD JENNIFER L | President & CEO | Buy | 5,263 | $7,526 |
| 2025-03-25 | GOOD JENNIFER L | President & CEO | Sell | 5,263 | $34,631 |
| 2025-03-12 | Simon Farrell | Chief Commercial Officer | Buy | 17,500 | $56,175 |
| 2025-03-12 | Simon Farrell | Chief Commercial Officer | Buy | 63,813 | $249,509 |
| 2025-03-12 | Simon Farrell | Chief Commercial Officer | Buy | 31,250 | $15,938 |
| 2025-03-12 | Simon Farrell | Chief Commercial Officer | Sell | 76,963 | $517,961 |
| 2025-03-12 | Simon Farrell | Chief Commercial Officer | Sell | 4,350 | $31,102 |
Source: SEC Form 4 filings · as of 2026-02-13